Ilumya (tildrakizumab) is administered intravenously every four weeks for the first four weeks, followed by a maintenance dose every eight weeks thereafter [1].
When does the initial dosing of Ilumya change?
After the initial loading doses, which are given at weeks 0 and 4, the dosing schedule shifts to a maintenance phase. This maintenance phase involves administering Ilumya every eight weeks [1].
What is the approved indication for Ilumya?
Ilumya is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].
How is Ilumya supplied and administered?
Ilumya is supplied as a solution for intravenous infusion. It is typically administered by a healthcare professional [1].
What is the recommended dosage strength for Ilumya?
The recommended dosage strength for Ilumya is 200 mg [1].
What are the key considerations for patients before starting Ilumya?
Before starting Ilumya, patients should be evaluated for tuberculosis infection and other infections. Patients should also be updated on all necessary immunizations before beginning treatment with Ilumya, as it may reduce the ability of the immune system to fight infections [1].
What is the mechanism of action of Ilumya?
Ilumya is a humanized IgG4, kappa monoclonal antibody that specifically binds to the p19 subunit of interleukin-35 (IL-35) and inhibits its interaction with its receptor. IL-35 is a cytokine that plays a role in inflammatory processes. By blocking IL-35, Ilumya helps to reduce inflammation associated with plaque psoriasis [1].
Where can I find more information on drug patents and exclusivity for Ilumya?
Information regarding drug patents and exclusivity for Ilumya and other pharmaceuticals can be found on DrugPatentWatch.com [2].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761074s000lbl.pdf
2. https://www.drugpatentwatch.com/